Spectrum Pharmaceuticals

.

FDA OK’s Spectrum Cancer Drug for Wider Use

Spectrum Pharmaceuticals

An Irvine drug maker, Spectrum Pharmaceuticals Inc., has said that it got regulatory approval for an expanded use of a cancer drug.

Spectrum said that the FDA approved Zevalin as an early treatment for a blood cancer, in patients with non-Hodgkin's lymphoma. The drug was used previously on patients whose tumors did not respond to other treatments.

Spectrum Pharmaceuticals inks 50:50 JV pact with Cell Therapeutics

Spectrum Pharmaceuticals inks 50:50 JV pact with Cell Therapeutics Spectrum Pharmaceuticals and Cell Therapeutics have entered into an agreement to form a 50:50 owned joint venture, RIT Oncology, to commercialize and develop Zevalin in the United States.

Latest News

Cracknell supports tax on sugary drinks in the UK
Patients less likely to die with more nurses, study
Gasoline Prices Drop Further in the Midwest and West due to Oversupply
Deutsche Bank Executives Face a Tough Turnaround Plan as Investors Lose Confiden
Viacom Misses Earnings Expectations for the Fifth Straight Quarter; CEO Takes a
Walt Disney Co. Reports Greater Than Expected First Fiscal Quarter Profits
Lara Casalotti finds stem cell donor
Sending mentally ill people long distances must stop, panel
Zenefits CEO Leaves Over Compliance Issues COO Takes Over
Apollo Education Group will be Acquired by a Group of Private Investors
BOJ’s Negative Interest Rate Expected to have Major Influence on Japan’s Banks
21st Century Fox Lowers Full Year Earnings Guidance
Syndicate content